U.S. regulators said on Thursday they approved a novel type of heart valve made by CryoLife Inc (CRY.N: Quote, Profile, Research), composed of human tissue with cells removed to potentially lower the risk of rejection.CryoLife shares rose as much as 14 percent on the New York Stock Exchange before easing to $7.47, still up a sharp 10.7 percent.The Food and Drug Administration said it cleared the product, which it called a "promising advance," to allow more options for patients, especi....
Healthcare Information And Resources
